Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open.

Luc BiedermannMarla C DubinskySéverine VermeireMarc FellmannSean GardinerPeter HurRajiv MundayatJulian PanésDavid T Rubin

Published in: Inflammatory bowel diseases (2022)

A continued favorable impact on HRQoL was revealed with long-term tofacitinib treatment in OCTAVE Open, regardless of baseline remission status or treatment history. (ClinicalTrials.gov; number: NCT01470612).

Keyphrases

ulcerative colitis
open label
randomized controlled trial
minimally invasive
type diabetes
systemic lupus erythematosus
phase ii
smoking cessation